The report expects APAT to rise 228.8% YoY despite EBITDA margin contraction of 187.3bps QoQ.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
1793 notes · 01 Oct 2026, 00:00 to 01 Nov 2026, 00:00 IST
The report expects revenue to grow 37.7% YoY but EBITDA margin to contract 406.3bps QoQ to 20.5%.
Read this note →The report expects EBITDA margin to fall 349.5bps QoQ to 7.5% despite 20% YoY revenue growth.
Read this note →The report expects APAT to rise sharply YoY and the rating was revised down from BUY to REDUCE with a raised target price.
Read this note →The report expects revenue to rise 38.5% YoY driven by ramp-up in the CDMO business.
Read this note →The report expects per-unit EBITDA to fall to INR 24.5/kg from INR 35.0/kg in Q1 despite 32.8% YoY revenue growth.
Read this note →The report expects EBITDA margin to decline 276.8bps QoQ to 22.6% despite 22% YoY revenue growth.
Read this note →The report expects revenue to grow 31% YoY but EBITDA margin to fall 417bps QoQ to 16.8%; the rating was revised from SELL to REDUCE.
Read this note →The report expects EBITDA margin to contract 335.4bps QoQ due to higher raw material prices and high-cost inventory.
Read this note →The report expects EBITDA margin to decline 452.7bps QoQ to 20.9% despite 30% YoY revenue growth.
Read this note →The report expects revenue and EBITDA to grow YoY and QoQ with EBITDA margin broadly stable at 34.2%.
Read this note →The report expects EBITDA margin to fall 406.9bps QoQ due to correction in finished product prices and higher energy costs despite falling ammonia prices.
Read this note →The report expects revenue and EBITDA to grow over 22% YoY, aided by improved Baker Hughes contract revenue.
Read this note →The report expects revenue to rise 14.4% YoY but EBITDA margin to contract 145.3bps QoQ due to higher raw material prices.
Read this note →The report states that PEPL's H1FY27 presales of INR 72.3bn grew 20% YoY, collections rose 16% YoY, retail occupancy stood at 99%, and a launch pipeline of over INR 400bn for H2FY27 supports achieving FY27 presales guidance of INR 350bn, while maintaining a BUY rating with a target price of INR 1,878.
Read this note →The report notes Sun Pharma approved a plan to raise up to Rs 10,000 crore via NCDs for funding and business expansion.
Read this note →The report notes Shyam Metalics secured strategic mining rights for the Phutamura coal block via investment in Alom Solar Private Limited.
Read this note →The report notes Vimag Labs commenced production at its Haryana facility and plans to invest Rs 50 crore to expand operations.
Read this note →The report notes KPIL secured new T&D orders worth Rs 2,225 crore, strengthening its order book.
Read this note →The report notes Vantrock plans to invest Rs 3,000 crore over four years to develop logistics and warehousing parks.
Read this note →The report lists Max Healthcare Institute among the top losers on 13 Oct, down 0.57-0.99%.
Read this note →The report lists Maruti Suzuki India among the top losers on 13 Oct, down 0.57-0.99%.
Read this note →The report lists Eternal among the top losers on 13 Oct, down 0.57-0.99%.
Read this note →The report lists Kotak Mahindra Bank among the top losers on 13 Oct, down 0.57-0.99%.
Read this note →The report lists Infosys among the top gainers on 13 Oct, up 4.13-8.42% along with other top gainers.
Read this note →